Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This study will establish the optimal therapeutic strategy for patients with a coronary
artery disease (CAD) and chronically treated with clopidogrel 75 mg/day requiring
co-administration of an anti-platelet treatment with P2Y12 antagonist and a PPI for
treatment/prevention of GI ulceration.
Phase:
N/A
Details
Lead Sponsor:
Ascopharm Groupe Novasco
Collaborators:
Groupe Hospitalier Pitie-Salpetriere Medco Health Solutions, Inc.